<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03856099</url>
  </required_header>
  <id_info>
    <org_study_id>PMC_TTAC-0001_03</org_study_id>
    <nct_id>NCT03856099</nct_id>
  </id_info>
  <brief_title>TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab</brief_title>
  <official_title>A Multicenter, Open-Label, Phase Ⅱ Clinical Trial to Evaluate the Safety and Efficacy of TTAC-0001, a Fully Human Monoclonal Antibody in Patients With Recurrent Glioblastoma Progressed on Bevacizumab Including Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmAbcine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmAbcine</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II, open-Label clinical trial to evaluate the safety and efficacy of
      TTAC-0001 in patients with recurrent glioblastoma who was progressed on bevacizumab including
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>until time of progressive disease or 1 year</time_frame>
    <description>The frequency and percentage of AEs will be presented by dose goup</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival rate at 4 months</measure>
    <time_frame>at the end of 4 months</time_frame>
    <description>The rate and 2-sided 95% confidence interval of progression free survival at the 4-month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival rate at 6 months</measure>
    <time_frame>at the end of 6 months</time_frame>
    <description>The rate and 2-sided 95% confidence interval of progression free survival at the 6-month</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>until time of progressive disease or time point of patients' death which come first assessed up to 1 year</time_frame>
    <description>Period from the date of the drug administration to the disease progression time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>until time point of patients' death up to 1 year</time_frame>
    <description>Period from the date of the drug administration to the time point of patient's death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>At every 2nd cycles until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year (every cycle is 28 days)</time_frame>
    <description>complete response (CR) or partial response (PR) by RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>At every 2nd cycles until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year (every cycle is 28 days)</time_frame>
    <description>complete response (CR), partial response (PR) or stable disease (SD) by RANO criteria</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>From screening visit to end of treatment visit (time of progressive disease or 1 year)</time_frame>
    <description>Presence anti-drug antibody (ADA)</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters - Cmax</measure>
    <time_frame>From screening visit to end of treatment visit (time of progressive disease or 1 year)</time_frame>
    <description>Maximum concentration of drug by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters - Cmin</measure>
    <time_frame>From screening visit to end of treatment visit (time of progressive disease or 1 year)</time_frame>
    <description>Minimum concentration of drug by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters - AUC0-t</measure>
    <time_frame>From screening visit to end of treatment visit (time of progressive disease or 1 year)</time_frame>
    <description>Area under the curve from baseline to each timepoint by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters -Tmax</measure>
    <time_frame>From screening visit to end of treatment visit (time of progressive disease or 1 year)</time_frame>
    <description>Time of Cmax by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters - CL</measure>
    <time_frame>From screening visit to end of treatment visit (time of progressive disease or 1 year)</time_frame>
    <description>Clearance by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters - Vd</measure>
    <time_frame>From screening visit to end of treatment visit (time of progressive disease or 1 year)</time_frame>
    <description>Volume of distribution by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters - Ke</measure>
    <time_frame>From screening visit to end of treatment visit (time of progressive disease or 1 year)</time_frame>
    <description>Elimination rate constant by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic parameters - T½</measure>
    <time_frame>From screening visit to end of treatment visit (time of progressive disease or 1 year)</time_frame>
    <description>Half-life by dose level</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in concentration of serum angiogenic factor or receptor</measure>
    <time_frame>From screening visit to end of treatment visit (time of progressive disease or 1 year)</time_frame>
    <description>VEGF, placental growth factor [PLGF], soluble vascular endothelial growth factor receptor [sVEGFR]-2, sVEGFR-1, etc.</description>
  </other_outcome>
  <other_outcome>
    <measure>DCE-MRI</measure>
    <time_frame>Screening visit, on Day8 and Day 15 of cycle 1, Day 28 of every 2nd cycle (1 cycle is 28 days, up to 1 year)</time_frame>
    <description>Blood flow parameter - iAUC, K-trans</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Recurrent Glioblastoma</condition>
  <arm_group>
    <arm_group_label>TTAC-0001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TTAC-0001 with dose assigned to each dose group will be administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTAC-0001</intervention_name>
    <description>Investigational product (IP): TTAC-0001
Treatment groups: 3 dose groups
Dose group A : TTAC-0001 16 mg/kg on D1 and D15
Dose group B : TTAC-0001 20 mg/kg on D1 and D15
Dose group C : TTAC-0001 24 mg/kg on D1 and D15
Cycle: 4 weeks (28 days per cycle)</description>
    <arm_group_label>TTAC-0001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of signed and dated informed consent prior to any study specific procedures,
             sampling or analyses.

          2. Aged at least 18 years old

          3. Patients must have a histologically proven diagnosis of glioblastoma/gliosarcoma

          4. Patients must have previous treatment including bevacizumab

          5. Patients must have a radiological diagnosis of recurrent/relapsed or progressive
             glioblastoma/gliosarcoma after bevacizumab including therapy according to response
             assessment in neuro-oncology (RANO) criteria

          6. At least one confirmed measurable lesion or non measurable lesion as determined by
             RANO criteria

          7. Patients must undergo IDH1 mutational testing on a tumor specimen before entering the
             study. Immunohistochemistry (IHC) is sufficient for enrollment, although DNA
             sequencing may also be performed as per local institutional guidelines. Patients are
             eligible regardless of their tumor status.

          8. Karnofsky Performance Status (KPS) ≥ 70

          9. A person who satisfies the following criteria in hematologic, renal, and hepatic
             function tests (1) Hematologic tests - Absolute neutrophil count (ANC) ≥ 1.5 x 109/L -
             Platelets ≥ 75 x 109/L

             - Hemoglobin ≥ 9.0 g/dL (2) Blood coagulation tests

             - Prothrombin time (PT) ≤ 1.5 x Upper limit of normal (ULN)

             - Activated partial thromboplastin Time (aPTT) ≤ 1.5 x ULN (3) Hepatic function tests

               -  Total bilirubin ≤ 1.5 x ULN

               -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 3 x ULN (4)
                  Renal function test

               -  Creatinine clearance (CrCl) ≥ 30 mL/minute calculated by Cockcroft-Gault formula

         10. Life expectancy of at least 12 weeks

         11. Females of child bearing potential must have a negative pregnancy test during
             screening and must not be breastfeeding or intending to become pregnant during the
             study.

         12. Male patients with female partners of child-bearing potential must be willing to use
             two forms of acceptable contraception, including one barrier method, during their
             participation in this study and for 16 weeks following the last dose of the study.
             Refer to section 10.5.1 Restrictions, permitted methods of contraception and
             definitions.

        Exclusion Criteria:

          1. Diagnosed with malignant tumors, except basal cell carcinoma, cutaneous squamous cell
             carcinoma, and noninvasive uterine cervical cancer treated within 2 years prior to
             receiving the first dose of treatment.

          2. The following concomitant diseases:

        (1) Uncontrolled hypertension (systolic blood pressure [SBP] &gt; 150 or diastolic blood
        pressure [DBP] &gt; 90 mmHg) (2) Uncontrolled seizures (3) Class III or IV heart failure
        according to New York Heart Association (NYHA) classification (4) Oxygen-dependent chronic
        disease (5) Active psychiatric disorder (schizophrenia, major depressive disorder, bipolar
        disorder etc.). Treated depression with ongoing antidepressant medication is not an
        exclusion.

        3) Not recovered from AEs &lt; National Cancer Institute -Common Terminology Criteria for
        Adverse Events (NCI-CTCAE) grade 2 caused by CCRT 4) Treatment with bevacizumab including
        therapy 2 weeks prior to receiving the first dose of treatment.

        5) Undergone major surgery requiring general anesthesia or a respiratory assistance device
        within 4 weeks prior to the baseline visit (within 2 weeks for video-assisted thoracoscopic
        surgery [VATS] or open-and-closed [ONC] surgery) 6) Treated with other investigational
        products within 4 weeks prior to the patient receiving the first dose of treatment.

        7) A known history of severe drug hypersensitivity or hypersensitivity to a therapy similar
        to the study drug 8) Unable to participate in the trial according to the investigator's
        decision. 9) Patient not eligible for sequential MRI evaluations are not eligible for this
        study 10) Previous therapy with VEGF-targeted agents except bevacizumab. 11) Known active
        hepatitis B or hepatitis C infection 12) Has received a live vaccine within 30 days prior
        to enrollment. Seasonal flu vaccines that do not contain live virus are permitted.

        13) Has had a serious or non-healing wound, ulcer, or bone fracture within 28 days prior to
        enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Seonyoung Lee, MPH</last_name>
    <phone>+8210-4360-2257</phone>
    <email>sylee@pharmabcine.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jinkyung Kim, BS</last_name>
    <phone>+827044466393</phone>
    <email>jinkyung.kim@pharmabcine.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford Avanced Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hary Priya Yerraballa</last_name>
      <phone>650-724-9363</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Cancer Institute &amp; Florida Hospital Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Thomas</last_name>
      <phone>407-303-7376</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Fluck</last_name>
      <phone>+61 3 9496 9912</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2019</study_first_posted>
  <last_update_submitted>April 12, 2020</last_update_submitted>
  <last_update_submitted_qc>April 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

